Claims for Patent: 8,936,804

Summary for Patent: 8,936,804

Title:	Use of vanadium compounds to accelerate bone healing
Abstract:	This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.
Inventor(s):	Lin; Sheldon Suton (Chatham, NJ), Paglia; David Naisby (New Britain, CT), O\'Connor; James Patrick (Fanwood, NJ), Breitbart; Eric (South Orange, NJ), Benevenia; Joseph (Montclair, NJ)
Assignee:	Rutgers, The State University of New Jersey (New Brunswick, NJ)
Application Number:	13/522,075
Patent Claims:	1. A method of promoting bone injury healing in a patient in need thereof, comprising locally administering to the bone injury site of said patient a therapeutically effective amount of a composition sterilized for in vivo bone administration comprising an insulin-mimetic vanadium compound and a pharmaceutically suitable carrier for localized bone site delivery. 2. The method of claim 1, wherein said vanadium compound is selected from the group consisting of vanadyl acetylacetonate (VAC), vanadyl sulfate (VS), vanadyl 3-ethylacetyl-acetonate (VET), and bis(maltolato)oxovanadium (BMOV). 3. The method of claim 1, wherein said vanadium compound is vanadyl acetyl-acetonate (VAC). 4. The method of claim 1, wherein said vanadium compound is directly administered to the bone injury site. 5. The method of claim 1, wherein said bone site is afflicted with a condition selected from the group consisting of bone fracture, bone trauma, arthrodesis and a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment, congenital bone loss, post traumatic bone loss, post-surgical bone loss, post infectious bone loss, allograft incorporation or bone radiotherapy treatment. 6. The method of claim 5, wherein said condition is selected from bone fractures, osseous defects, and delayed unions and non-unions. 7. The method of claim 1, wherein the method is used in conjunction with an allograft, autograft or orthopedic biocomposite. 8. The method according of claim 1, wherein said vanadium compound is locally administered by a bone graft biocomposite containing said vanadium compound. 9. The method of claim 8, wherein the bone graft composite is selected from the group consisting of autografts, allografts, xenografts, alloplastic grafts, and synthetic grafts. 10. The method of claim 1, wherein said method comprises co-administering a cytotoxic agent, cytokine or growth inhibitory agent with said vanadium compound. 11. The method of claim 1, wherein the method is used in conjunction with an external bone growth stimulator. 12. The method of claim 1, wherein the method comprises co-administering a bioactive bone agent with said vanadium compound. 13. The method of claim 12, wherein said bioactive bone agent is selected from the group consisting of peptide growth factors, anti-inflammatory factors, pro-inflammatory factors, inhibitors of apoptosis, MMP inhibitors, and bone catabolic antagonists. 14. The method of claim 13, wherein said peptide growth factor is selected from the group consisting of IGF (1,2), PDGF (AA, AB, BB), BMPs, FGF (1-20), TGF-beta (1-3), aFGF, bFGF, EGF, VEGF, parathyroid hormone (PTH), and parathyroid hormone-related protein (PTHrP). 15. The method of claim 13, wherein said anti-inflammatory factor is selected from the group consisting of anti-TNF.alpha., soluble TNF receptors, IL1ra, soluble IL1 receptors, IL4, IL-10, and IL-13. 16. The method of claim 13, wherein said bone catabolic antagonist is selected from the group consisting of bisphosphonates, osteoprotegerin, and statins. 17. The method of claim 1, wherein said patient is a mammalian animal. 18. The method of claim 1, wherein said patient is a human. 19. The method of claim 1, wherein said patient is a non-diabetic human. 20. A method of promoting bone injury healing comprising locally administering to a bone injury site of a patient in need thereof a therapeutically effective amount of a composition sterilized for in vivo bone administration comprising an insulin-mimetic vanadium compound. 21. The method of claim 20, wherein said composition comprises at least one biocompatible carrier. 22. The method of claim 21, wherein said biocompatible carrier is selected from the group consisting of poly-lactic acid, poly-glycolic acid, and copolymers of poly-lactic acid and poly-glycolic acid. 23. The method of claim 21, wherein said biocompatible carrier comprises at least one biodegradable fatty acid or a metal salt thereof. 24. The method of claim 23, wherein said fatty acid, is selected from the group consisting of palmitic acid, stearic acid, oleic acid, myristic acid, and metal salts thereof. 25. The method of claim 21, wherein said biocompatible carrier comprises a salt selected from the group consisting of porous or non-porous calcium phosphates, porous or non-porous hydroxyapatites, porous or non-porous tricalcium phosphates, porous or non-porous tetracalcium phosphates, porous or non-porous calcium sulfates, and combinations thereof. 26. The method of claim 20, further comprising treating said patient with at least one procedure selected from the group consisting of bone autograft, bone allograft, autologous stem cell treatment, allogeneic stem cell treatment, chemical stimulation, electrical stimulation, internal fixation, and external fixation.

Details for Patent 8,936,804

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2030-01-14